Physician profile
Linh Dang
NPI 1154425213
$9,020.64
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $1,278 · 2021: $2,373 · 2022: $1,616 · 2023: $1,413 · 2024: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,957.73 | 2021-2023 | Vercise |
| Mdd US Operations, LLC | $1,134.38 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $986.35 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $931.40 | 2020-2024 | Ingrezza, Ongentys |
| Medtronic, INC. | $477.99 | 2021-2023 | Activa Pc |
| Novartis Pharmaceuticals Corporation | $380.94 | 2019-2023 | |
| Kyowa Kirin, INC. | $280.44 | 2019-2023 | Nourianz |
| Abbvie INC. | $256.50 | 2021-2024 | Ubrelvy, Qulipta |
| Medtronic USA, INC. | $246.34 | 2019 | |
| Pfizer INC. | $202.08 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $171.05 | 2019-2023 | |
| Acorda Therapeutics, INC | $162.11 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $147.57 | 2022 | |
| Biogen, INC. | $127.90 | 2020-2024 | Vumerity, Avonex |
| Lundbeck LLC | $123.63 | 2019-2024 | Vyepti, Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linh Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.